This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kissei Pharmaceutical Co., Ltd
Drug Names(s): mitiglinide, KAD-1229, Glinsuna, Metgluna (with metformin), Glubes (with voglibose)
Description: Glinsuna, a member of the meglitinide class of compounds, is an insulin secretagogue thatlowers post-meal glucose levels by improving the body's own ability to produce insulin. Glinsuna promotes insulin secretion by closing the ATP-sensitive K(+) channels in pancreatic beta-cells. It demonstrates effects promptly after dosing, thereby it brings insulin secretion closer to its natural patterns and improves postprandial hyperglycemia.
Deal Structure: Mitiglinide was originally developed by Kissei.
Takeda and Kissei
In August 2002, Kissei Pharmaceutical Co. and Takeda Chemical Industries jointly announced that both parties entered into a co-marketing agreement for mitiglinide (KAD-1229) in Japan. Under the agreement, Kissei will co-market the product with Takada under the same product name in Japan after obtaining the NDA approval.
Kissei and Elixir
In March 2006, Elixir Pharmaceuticals announced that the Company has signed a definitive agreement with Kissei Pharmaceutical for the exclusive right to develop and commercialize Glufast in the United States, Canada, and Latin America.
Under the terms of the licensing agreement with Kissei, Elixir will have the right to develop and commercialize Glufast, as well future products that combine Glufast with other compounds, in the United States, Canada, and Latin America. For these rights, Elixir will make payments to Kissei based on predetermined milestones,...See full deal structure in Biomedtracker
Partners: Elixir Pharmaceuticals, Inc. Takeda Pharmaceutical Company Ltd
Additional information available to subscribers only: